Exenatide acetate hmoovyog ib hom kev hloov kho kev ua haujlwm peptide compound nrog tshwj xeeb thiab ruaj khov physicochemical txheeb xyuas cov yam ntxwv. Tus txheeb ze molecular hnyav ntawm lub active peptide yog hais txog 4100-4200, thiab nws tshwm li dawb khov- qhuav hmoov nyob rau hauv chav tsev kub. Nws muaj dej solubility zoo thiab kev daws teeb meem. Tom qab cov khoom siv peptide hloov kho, nws cov enzymatic hydrolysis tsis kam yog qhov zoo dua, thiab nws cov khoom siv physicochemical txawv ntawm cov khoom siv ntuj GLP-1. Cov tshuaj no tso siab rau cov peptide chain modification technology thiab muaj cov tshuaj teb cov yam ntxwv uas txawv ntawm ntuj active peptides. Nws cov khoom zoo physicochemical xws li spatial conformation stability thiab molecular binding affinity tuaj yeem tshawb nrhiav ntxiv los ntawm kev sim physicochemical tshwj xeeb. Cov tshuaj no muaj qhov tshwj xeeb ntse ntshav aldohexose cov lus teb hom, lipid metabolism hauv kev tswj muaj peev xwm, thiab sib txawv kev nyab xeeb rau kev kho ua ke. Cov kab lus no tau sau tseg cov yam ntxwv sib txawv ntawm cov tshuaj pharmacological ntawm cov tshuaj, suav nrog cov txheej txheem ntawm kev tswj hwm tus kheej attenuation ntawm pharmacological kev ua haujlwm tom qab cov ntshav aldohexose rov qab mus rau qhov qub, cov yam ntxwv tsis tshua muaj kev pheej hmoo ntawm hypoglycemia, kev txhim kho kev tswj hwm ntawm lub cev lipid metabolism spectrum, thiab kev siv sab hauv hauv kev siv hauv kev sib xyaw ua ke ntawm cov tshuaj hypoglycemic. Cov tshuaj hypoglycemic.
Peb cov khoom
ExenatideCOA
Qhov tsis qab los noj mov thaum ntxov yog qhov tseem ceeb los ntawm lub ntsiab lus tseem ceeb
Cov nyiaj them rov qab mechanism ntawm lub cev nyob rau hauv nruab nrab thiab tom qab theem yuav tag nrho counteract lub hauv paus inhibitory nyhuv
Nyob rau hauv nruab nrab thiab lig theem ntawm cov tshuaj, lub cev metabolism thiab neural regulatory system yuav ua kom tiav ib tug khov kho - lub xeev reset, thiab lub hypothalamus yuav nquag hloov mus rau cov tshuaj qhov kev txiav txim, recalibrate lub noj mov pib pib, maj offsetting cuam tshuam cov nyhuv ntawm cov tshuaj nyob rau hauv txoj kev ntawm kev txhawb cov zaub mov thiab satiety. Lub hauv paus inhibitory nyhuv uas thaum xub thawj ua rau tsis qab los noj mov yuav ua rau tsis muaj zog thiab tag nrho nws lub luag haujlwm tseem ceeb.
Nyob rau hauv thawj theem, tsis muaj kev kam rau siab buffering nyob rau hauv lub cev, thiab qhov no mechanism yog lub tsuas dominant trigger.
Nyob rau theem pib ntawm kev siv tshuaj, lub cev tseem tsis tau tsim muaj kev hloov kho tshuaj lossis kev them nyiaj rov qab muaj peev xwm, thiab lub hauv paus paj hlwb muaj kev cuam tshuam rau kev cuam tshuam tshuaj.
Lub sijhawm no, kev hloov pauv ntawm txoj hauv kev pub mis hauv nruab nrab yog qhov tseem ceeb ua rau muaj kev noj qab haus huv tsawg. Txawm li cas los xij, tom qab kev hloov pauv ntawm lub plab zom mov thiab rov pib dua ntawm neural thresholds nyob rau hauv nruab nrab thiab lig theem, qhov kev cuam tshuam hauv nruab nrab no tsis muaj txiaj ntsig, yog li nws tsuas yog thawj qhov tseem ceeb thiab tsis koom nrog kev tswj hwm ntawm cov tsos mob hauv nruab nrab thiab lig theem.
Kev cuam tshuam tshuaj hauv nruab nrab yog rau kev hloov pauv mus ib ntus yam tsis muaj kev hloov pauv mus tas li
Exenatide tsuas yog tswj hwm ib ntus ntawm cov teeb liab hloov pauv ntawm cov paj hlwb hypothalamic, thiab tsuas yog kev hloov kho ua haujlwm ib ntus ntawm qib pharmacological. Nws tsis ua kom puas los yog rhuav tshem cov ntaub so ntswg ntawm cov hlab ntsha hauv nruab nrab txoj hauv kev thiab kev tswj cov kab mob hauv lub cev. Tsis muaj cov organic lossis kev ua haujlwm tas mus li puas tsuaj, yog li yuav tsis muaj sijhawm ntev - lub sij hawm qab los noj mov, tsuas yog luv luv - lub sij hawm txo qhov txaus siab noj.
Autonomous attenuation ntawm pharmacological kev ua si thiab inherent tsis tshua muaj kev pheej hmoo mechanism ntawm hypoglycemia tom qab ib txwm ntshav aldohexose qib.
Exenatide acetate hmoovNws muaj qhov tshwj xeeb ntawm cov ntshav aldohexose concentration txuas nrog cov tshuaj teb tus yam ntxwv, thiab nws cov qib pharmacological ua kom tiav yog nyob ntawm qhov hloov pauv hloov pauv ntawm lub cev cov ntshav aldohexose concentration, tsis tas yuav tsum muaj cov nyhuv hypoglycemic tas li. Cov yam ntxwv no ib txwm ua rau nws tsis tshua muaj kev pheej hmoo ntawm tus kheej hypoglycemia, uas txawv ntawm cov khoom siv hluavtaws hluavtaws hluavtaws. Qhov kev txiav txim siab tshwj xeeb tuaj yeem muab faib ua peb qhov loj:
(I) Pharmacological activation muaj ntshav aldohexoseqhov pib dependence
Lub hom phiaj ntawm kev ua kom lub cev ntawm cov tshuaj no tsuas yog ua kom muaj kev ua kom muaj zog thaum lub cev cov ntshav aldohexose concentration ntau dua li cov qauv ntawm lub cev. Qhov siab dua qhov txawv txav ntawm cov ntshav aldohexose, qhov tseem ceeb ntawm cov molecular binding efficiency thiab kev siv tshuaj pharmacological, uas tuaj yeem kho cov kab mob pathological ntawm hyperglycemia. Thaum lub cev cov ntshav aldohexose concentration maj mam poob mus rau qhov pib ntawm lub cev, nws lub hom phiaj receptor binding kev ua haujlwm yuav ua rau nws tus kheej thiab maj mam ua tsis muaj zog, thiab cov tshuaj tswj kev siv tshuaj yuav txo qis, tsis txuas ntxiv tso tawm cov teebmeem hypoglycemic, thiab tsis muaj kev coj noj coj ua ntawm kev cuam tshuam txuas ntxiv hauv cov ntshav hauv tsev.
(II) Kev tswj cov khoom ntawm physiological ntshav aldohexosetsis muaj kev cuam tshuam ntau dhau
Cov pa hypoglycemic cov neeg ua haujlwm feem ntau yog cov khoom siv tshuaj kho mob tas li, uas tuaj yeem yooj yim ua rau kev kho cov ntshav aldohexose ntau dhau thiab ua rau muaj cov tsos mob ntawm tus kheej hypoglycemic.
Txoj kev tswj hwm ntawm exenatide belongs rau "ntawm- qhov xav tau teb" physiological kho, uas tsuas yog ua lub luag haujlwm tswj hwm hauv pathological hyperglycemia thiab tsis cuam tshuam rau cov ntshav aldohexose ib txwm nyob hauv lub cev, kom zam dhau qhov kev pheej hmoo ntawm cov tshuaj uas ua rau muaj ntshav siab ntau dhau ntawm cov tshuaj aldohexose hauv cov hauv paus hniav.
(III) Ua kom haum rau qhov ruaj khov- lub xeev txoj cai atherosclerosis ntawm endogenous ntshav aldohexosehauv lub cev
Lub pharmacological teb atherosclerosis ntawm cov tshuaj no yog heev sib xws nrog lub ntuj cov ntshav aldohexose regulation atherosclerosis ntawm tib neeg lub cev, thiab muaj peev xwm cia siab rau lub cev tus kheej cov ntshav aldohexose tawm tswv yim system kom ua tau tus kheej - kev cai ntawm pharmacological kev ua ub no. Nyob rau hauv lub cev lub cev ntawm cov ntshav qab zib kom ruaj khov, cov tshuaj tseem nyob rau hauv ib qho kev ua haujlwm qis lossis so hauv lub xeev, yam tsis muaj kev cuam tshuam cov kab mob endogenous ntshav qab zib thiab yuav tsum muaj kev tswj hwm nyiaj txiag ntxiv. Qhov no ua kom muaj kev nyab xeeb ntawm cov tshuaj los ntawm kev xav txog kev hloov pauv ntawm lub cev, ua rau muaj qhov tshwm sim hauv kev kho mob ntawm cov ntshav qab zib tsawg.
Cov txheej txheem ntawm inducing me ntsis nce qhov kev pheej hmoo ntawm hypoglycemia thaum ua ke nrog lwm cov tshuaj hypoglycemic.
Thaum twgexenatide acetate hmoovyog siv ib leeg, qhov tshwm sim ntawm hypoglycemia yog tsawg heev. Txawm li cas los xij, hauv cov xwm txheej kho mob uas nws tau koom nrog lwm hom tshuaj hypoglycemic, tej zaum yuav muaj kev pheej hmoo ntawm hypoglycemia nce me ntsis. Qhov tshwm sim no tsis yog tshwm sim los ntawm kev siv tshuaj toxicity, tab sis los ntawm qhov tsis txaus ntseeg ruaj khov los ntawm ntau cov tshuaj pharmacological, uas yog qhov tsis tshua muaj tshuaj tsis haum tshuaj. Cov laj thawj tshwj xeeb tuaj yeem muab faib ua peb lub ntsiab lus:
Ntau cov tshuaj hypoglycemic pharmacological ua rau muaj kev nce ntxiv: Lwm cov tshuaj hypoglycemic cov tshuaj feem ntau yog nyob rau hauv ib qho kev siv cov tshuaj hypoglycemic tsis tu ncua thiab tsis tswj hwm los ntawm cov ntshav aldohexose concentration. Thaum cov tshuaj no siv ua ke nrog exenatide, cov nyhuv hypoglycemic ntawm cov tshuaj ib txwm siv, ua ke nrog rau ntawm -xav tau cov nyhuv hypoglycemic ntawm exenatide, yuav tsim cov nyhuv bidirectional hypoglycemic nce, tshaj qhov nyiaj them rov qab ntau ntawm cov ntshav aldohexose kev tswj hwm hauv lub cev, uas tuaj yeem yooj yim ua rau cov ntshav ntau dhau. hypoglycemia.
Offset ntshav aldohexose buffering tiv thaiv mechanism ntawm cov tshuaj nws tus kheej: Thaum exenatide yog siv ib leeg, nws muaj peev xwm tsim ib tug natural kev nyab xeeb buffering barrier los ntawm kev cia siab rau cov ntshav aldohexose nyob ntawm kev ua si attenuation yam ntxwv. Txawm li cas los xij, nyob rau hauv lub xeev ntawm kev siv tshuaj sib xyaw ua ke, cov nyhuv hypoglycemic sab nraud yuav ua rau txo qis hauv paus ntawm hypoglycemia, rhuav tshem cov tshuaj hloov pauv ntawm cov tshuaj nws tus kheej, thiab cuam tshuam cov txiaj ntsig ntawm kev ua haujlwm tsis ua haujlwm tom qab cov ntshav aldohexose poob, uas tsis tuaj yeem tiv thaiv cov ntshav aldohexose tsis tu ncua.
Muaj cov yam ntxwv sib txawv hauv glycogen reserves thiab metabolic them peev xwm ntawm cov tib neeg sib txawv, thiab qee cov neeg muaj cov ntshav tsis muaj zog aldohexose regulation reserves. Raws li kev cuam tshuam ntawm ntau cov tshuaj synergistic hypoglycemic therapy, qhov tsis muaj zog endogenous them nyiaj tsis tuaj yeem kho cov ntshav aldohexose hloov pauv tau los ntawm cov teebmeem hypoglycemic ntau dhau. Muab piv nrog cov tshuaj ib leegexenatide acetate hmoov, nws yog qhov yooj yim dua rau kev kho mob tshwm sim ntawm cov ntshav qis aldohexose, uas tag nrho nce qhov tshwm sim ntawm hypoglycemia hauv cov pejxeem.
Cov ntaub ntawv
Zhao Zeyu Kev Tshawb Fawb ntawm cov ntshav aldohexose homeostasis tiv thaiv mechanism thiab kev nyab xeeb tshuaj ntawm cov ntse teb hypoglycemic peptides [J]. Phau ntawv Journal of Modern Clinical Pharmacology, 2024, 40 (3): 198-203
Miller SJ, Carter L D. Lipid profile remodeling teebmeem ntawm glucagon-zoo li peptide analogs hauv metabolic ntshawv siab[J]. European Journal of Pharmacology, 2023, 952: 175892.
Lin Junkai Kev tshuaj xyuas ntawm qhov kev pheej hmoo superposition nyhuv thiab kev kho mob hloov kho lub tswv yim ntawm kev cuam tshuam nrog cov tshuaj hypoglycemic [J]. Kev Tshawb Fawb Kev Tshawb Fawb hauv Kev Siv Tshuaj General, 2023, 21 (12): 145-149
Kev txhaj tshuaj Exenatide (https://medlineplus.gov/druginfo/meds/a605034.html)
Exenatide acetate (https://aapep.bocsci.com/product/exenatide-acetate-cas-914454-01-6-474907.html)
FAQ
Yog lawm, qhov tshwj xeeb ntawm cov ntshav aldohexose qhov pib ua haujlwm ntawm cov tshuaj no tso cai rau nws tsuas yog siv cov tshuaj hypoglycemic hauv lub xeev hyperglycemic. Tom qab cov ntshav aldohexose ib txwm muaj, qhov ua tau zoo ntawm cov tshuaj ib txwm poob qis yam tsis muaj kev cuam tshuam hypoglycemic. Thaum siv ib leeg ua tus qauv, cov tsos mob hypoglycemic tsis zoo li tshwm sim.
Lub hom phiaj tseem ceeb yog los kho qhov sib npaug tag nrho ntawm cov ntshav lipid Cheebtsam, uas tuaj yeem tsis tsuas yog tshem tawm cov lipids hauv cov ntshav xwb, tab sis kuj nce qhov feem ntawm kev tiv thaiv lipids, kho cov kab mob lipid metabolism tsis zoo, tsis yog tsuas yog txo qee cov ntshav lipid index.
Tsis raug cais raws li kev pheej hmoo siab -, qhov kev pheej hmoo no tsuas yog nce me ntsis nrog tus nqi qis tag nrho. Los ntawm kev tswj hwm qhov ntau npaum ntawm cov tshuaj sib xyaw ua ke thiab saib xyuas cov ntshav aldohexose hloov pauv, cov xwm txheej txawv txav tuaj yeem zam tau yam tsis muaj kev phom sij loj hauv chaw kho mob.
Cim npe nrov: Tuam Tshoj exenatide acetate manufacturers, lwm tus neeg
